证券代码：688578 证券简称：艾力斯 公告编号：2025-020 股东上海艾祥企业发展中心（有限合伙）、南通艾耘企业发展中心（有限合伙）及 其一致行动人杜锦豪、上海乔可企业发展有限公司、JEFFREY YANG GUO 及 JENNIFER GUO 保证向上海艾力斯医药科技股份有限公司提供的信息真实、准确、完整，没有虚 假记载、误导性陈述或重大遗漏。 本公司董事会及全体董事保证公告内容与信息披露义务人提供的信息一致。 重要内容提示： | 权益变动方向 | 比例增加□ | | 比例减少 | | --- | --- | --- | --- | | 权益变动前合计比例 | 53.05% | | | | 权益变动后合计比例 | 51.87% | | | | 本次变动是否违反已作出的承 诺、意向、计划 | 是□ | 否 | | | 是否触发强制要约收购义务 | 是□ | 否 | | 一、 信息披露义务人及其一致行动人的基本信息 1.身份类别 投资者及其一致行动人的身份 控股股东/实际控制人及其一致行动人 □其他 5%以上大股东及其一致行动人 □合并口径第一大股东及其一致行动人（仅适用 于无控股股东、实际控制人 ...

今日(9月1日)A股共99只个股发生大宗交易，总成交28.0亿元，其中艾力斯、海光信息、光启技术成交 额居前，成交额依次为5.66亿元、2.61亿元、2.19亿元。 机构专用席位买入额排名：艾力斯(3.83亿元)、海光信息(2.61亿元)、冠捷科技(8004万元)、南京化纤 (7843.46万元)、方正科技(6551.8万元)、德福科技(4201.2万元)、康龙化成(4041.7万元)、力鼎光电 (2460.48万元)、立高食品(2338.41万元)、易瑞生物(2240万元)、华虹公司(2207.9万元)、川能动力(1509 万元)、盟固利(1024.53万元)、瑞泰新材(1014.12万元)、御银股份(900.98万元)、海亮股份(757.84万元)、 电声股份(743.69万元)、普路通(679.47万元)、博迁新材(678.75万元)、电光科技(409.24万元)、园林股份 (404.88万元)、神通科技(402.84万元)、雪龙集团(402.46万元)、德龙激光(274.89万元)、北京君正(260.37 万元)、和而泰(239.6万元)、凯美特气(232.64万元)、爱博医疗(204.79万元)、瑞 ...

Group 1 - The core viewpoint of the report indicates that the China Europe Medical Health Fund, managed by Guo Lan and Zhao Lei, has achieved a year-to-date return of 28.82%, outperforming other funds in the same category [1] - The fund has increased its holdings in the innovative pharmaceutical and medical device industry chain, particularly in Elysium (688578.SH) [1] - The top ten holdings of the fund include prominent companies such as WuXi AppTec (603259), Hengrui Medicine (600276), and Kanglong Chemical (300759), with significant investments in these firms [2][3] Group 2 - Elysium's shareholding has increased by 2627.32% compared to the end of last year, indicating a strong bullish sentiment [3] - Notable reductions in holdings include Hengrui Medicine, which decreased from 67.17 million shares to 57.49 million shares, and Kanglong Chemical, which fell from 72.29 million shares to 63.40 million shares [3] - The report highlights that major players like Mindray Medical and Aier Eye Hospital have dropped to the list of hidden heavyweights due to significant reductions in their holdings [3] Group 3 - The report outlines the cumulative sell amounts for various stocks, with Mindray Medical leading at approximately 1.77 billion yuan, followed by Hengrui Medicine at around 749 million yuan [4] - The report emphasizes that the pharmaceutical industry will continue to rely on innovation, consumer recovery, and domestic substitution as core growth drivers in the second half of the year [4] - The company plans to maintain a long-term value investment framework, focusing on innovative pharmaceuticals, OTC, and consumer healthcare sectors [5]

- The "PB-ROE-50" strategy is based on the idea of identifying market expectation gaps and enhancing portfolio returns by incorporating surprise factors such as SUE and ROE year-on-year growth. It selects 50 stocks to construct the portfolio using the PB-ROE pricing model derived from Wilcox (1984)[29][33][36] - The "PB-ROE-50" strategy achieved positive excess returns in August 2025 for the CSI 800 and the entire market stock pools, with excess returns of 5.22% and 7.61%, respectively. However, it recorded a negative excess return of -0.54% for the CSI 500 stock pool[29][33][36] - The "Upward Count Proportion Sentiment Indicator" calculates the proportion of stocks in the CSI 300 index with positive returns over the past N days. It is used to gauge market sentiment, with higher proportions indicating optimistic sentiment. The formula is: CSI 300 Index N-day Upward Count Proportion = Number of CSI 300 Index constituent stocks with returns > 0 in the past N days / Total number of constituent stocks[12][13][15] - The "Upward Count Proportion Sentiment Indicator" is smoothed using two different window periods (N1=50, N2=35) to generate fast and slow lines. When the fast line exceeds the slow line, it signals a bullish market sentiment[13][15][16] - The "Moving Average Sentiment Indicator" uses eight moving averages (parameters: 8, 13, 21, 34, 55, 89, 144, 233) to assess the sentiment state of the CSI 300 index. The indicator assigns values based on the range of the moving averages, with values of -1, 0, or 1 corresponding to different sentiment states[19][24][23] - The "Moving Average Sentiment Indicator" signals a bullish sentiment when the current price exceeds the values of more than five moving averages[19][24][23] - The "Fund Concentration Degree Tracking" uses the standard deviation of cross-sectional returns of concentrated fund portfolios as a proxy for fund concentration. Lower standard deviation indicates higher concentration, while higher standard deviation suggests concentration is breaking down[25][28][26] - The "Institutional Research Strategy" includes public fund research stock selection and private fund research tracking strategies. It selects stocks based on the number of times a company is researched and its relative performance before the research. In August 2025, the public fund strategy recorded an excess return of -1.33%, while the private fund strategy recorded -5.05%[37][39][40] - The "Relaxed Interest-Bearing Debt Ratio" is calculated as: (Short-term loans + Interest payable + Transactional financial liabilities + Payable short-term bonds + Lease liabilities + Long-term loans + Payable bonds + Long-term payables + Other current liabilities + Liabilities classified as held-for-sale + Non-current liabilities due within one year) / Total assets. It is used to identify stocks with high liquidity risk[42][43][45] - The "Financial Cost Burden Ratio" is calculated as: Financial expenses: Interest expenses / Earnings before interest and taxes (EBIT). It measures the pressure companies face in paying interest costs. Stocks with high ratios are flagged for potential financial risk[46][47][48]

Investment Rating - The investment rating for the company is "Buy" (maintained) [1][6] Core Views - The company achieved a revenue of 2,018 million in 2023, with a year-on-year growth of 155%, and is projected to reach 5,088 million by 2025, reflecting a growth rate of 43% [1] - The net profit attributable to the parent company is expected to grow significantly, from 644 million in 2023 to 1,808 million in 2025, indicating a growth rate of 26% [1] - The report highlights the strong performance of the drug Vomeletin, which is expected to drive revenue growth and profitability [4][5] Financial Performance Summary - The company reported a revenue of 2,374 million in the first half of 2025, a year-on-year increase of 50.57%, and a net profit of 1,051 million, up 60.22% [2] - The earnings per share (EPS) are projected to increase from 3.18 in 2024 to 4.02 in 2025, and further to 4.78 in 2026 [1][5] - The company's gross margin is expected to remain stable at 96% from 2024 to 2027 [5] Pipeline and Product Development - The company is transitioning from a single product operation to a product matrix management phase, with multiple drugs in the pipeline [4] - Vomeletin has shown promising results in clinical trials, particularly for patients with brain metastases, and is expected to expand its indications [4] - The company is collaborating with international partners to accelerate the development of Vomeletin for various NSCLC mutations [4] Market Position and Strategy - The report emphasizes the differentiated advantages of Vomeletin, including its safety profile and efficacy across various mutation types, which are expected to enhance its market value [4] - The company is preparing for the commercialization of other products, such as Pralsetinib, which is anticipated to be launched in 2026 [4] - The overall strategy focuses on leveraging strong clinical evidence to support the long product lifecycle and maintain competitive advantages in the market [4]

Core Insights - The article highlights the recent movements of prominent fund managers in the public fund sector, focusing on their investment strategies and the performance of their funds in 2025 [1][2]. Group 1: Zhang Kun's Strategy - Zhang Kun has reduced his holdings in Meituan by 46.43% while increasing his position in Beike, indicating a continued focus on domestic demand logic [2][3]. - The E Fund Blue Chip Select Fund, managed by Zhang Kun, has a current scale of 34.943 billion and a year-to-date return of 12.85% [3]. - The fund's hidden heavyweights include Focus Media and Meituan, with Focus Media's holdings increasing by 13.76% [3]. - Zhang Kun believes that the current pessimism regarding domestic demand is unfounded and anticipates a positive feedback loop in domestic consumption [4]. Group 2: Ge Lan's Focus on Innovation - Ge Lan's China Europe Medical Health Fund has achieved a year-to-date return of 28.82%, with significant investments in the innovative drug sector [5]. - The fund's hidden heavyweights include Huadong Medicine and Zai Lab, with a notable increase of 2627.32% in holdings of Ailisi [5][6]. - Ge Lan emphasizes that innovation, consumption recovery, and domestic substitution will drive growth in the pharmaceutical industry in the second half of 2025 [6]. Group 3: Fu Pengbo's Growth Strategy - Fu Pengbo's Ruiyuan Growth Value Fund has a year-to-date return of 48.50%, leading among large-scale public funds [7]. - The fund has significantly increased its holdings in Alibaba and BYD by 161.10% and 184.78%, respectively, focusing on high-growth sectors like technology and manufacturing [7]. - Fu Pengbo plans to continue emphasizing sectors such as electronics, internet technology, and precision manufacturing, while also adapting to market conditions [8].

Group 1 - The core viewpoint is that the innovative drug sector is experiencing significant growth, driven by strong mid-year performance from multiple companies and increased market liquidity and risk appetite [2][3] - The Shanghai Stock Exchange Sci-Tech Innovation Board Biopharmaceutical Index (000683) has risen by 4.02%, with notable increases in constituent stocks such as Maiwei Biotech (688062) up 20.00% and ZhiXiang JinTai (688443) up 11.60% [1][2] - The Sci-Tech Biopharmaceutical ETF (588250) closely tracks the performance of the Biopharmaceutical Index and has also seen a rise of 4.12%, with the latest price reported at 1.34 yuan [1][2] Group 2 - The top ten weighted stocks in the Biopharmaceutical Index account for 50.27% of the index, including companies like United Imaging Healthcare (688271) and BeiGene (688235) [3] - Investment strategies are recommended to focus on domestic clinical CROs benefiting from supportive policies, life sciences upstream companies with recovering overseas business, and companies involved in weight loss drugs, Alzheimer's treatments, ADCs, and AI concepts [2]

Market Overview - A-shares experienced slight fluctuations with major indices like the Shenzhen Component Index, CSI 300, and STAR 50 reaching new highs, while the ChiNext Index surpassed 2900 points [1] - The market saw more gainers than losers, with stable trading volume [1] Sector Performance - The Shanghai Composite Index closed at 3862.65, up by 0.12%, while the Shenzhen Component Index rose to 12710.24, up by 0.11%. The ChiNext Index increased by 0.55% to 2906.03 [2] - Sectors such as gold, pharmaceuticals, advertising, and general retail showed significant gains, while aerospace equipment, glass fiber, insurance, and wind power equipment faced declines [2] Gold Market Dynamics - Gold prices surged, leading to a collective rise in gold stocks, with the sector index increasing over 4% to reach a historical high. Trading volume approached the previous day's total within just half a day [3] - International spot gold prices saw a substantial increase, with domestic gold futures also rising significantly, surpassing 800 yuan per contract, marking a two-and-a-half-month high [4] Geopolitical Influences - Rising geopolitical tensions, including attacks on Russian oil export terminals and ongoing conflicts in Gaza, have heightened risk aversion, boosting gold's appeal as a safe-haven asset [5] - Concerns over global economic slowdown were exacerbated by the U.S. imposing a 50% tariff on Indian goods, further enhancing gold's attractiveness [5] Pharmaceutical Sector Activity - The pharmaceutical and biotechnology sector rebounded, with sub-sectors like chemical drugs, innovative drugs, and weight-loss drugs collectively rising over 2%. Companies like Hai Chen Pharmaceutical and Yi Pin Hong saw significant stock price increases [6] - Hong Kong's pharmaceutical stocks also performed strongly, with indices like the Hong Kong Stock Connect Innovative Drug Index rising over 4% [9] Fund Activity in Pharmaceuticals - A significant number of pharmaceutical companies reported revenue growth in their semi-annual reports, with 67 out of over 100 companies achieving year-on-year revenue increases [11] - Prominent fund managers have increased their holdings in pharmaceutical stocks, indicating a bullish outlook for the sector [12]

1. Report Industry Investment Rating - Goldman Sachs maintains an "Overweight" stance on Chinese stocks; Standard Chartered Bank maintains an "Overweight" rating on Chinese stocks in its "2025 H2 Global Market Outlook" [38] 2. Core Viewpoints of the Report - China's economic sentiment generally continues to expand, with the official manufacturing PMI, non - manufacturing PMI, and composite PMI in August showing month - on - month increases [2][20] - The overseas business of futures companies is accelerating development, driven by policy support and the concentrated overseas expansion of Chinese enterprises [3] - The bond market is expected to have limited adjustment space and may continue to consolidate in the short term [26] - The A - share market may show a phased shock consolidation feature in September, with market hotspots in a rotation state [38] 3. Summary by Directory 3.1 Macro Data Overview - In Q2 2025, GDP at constant prices increased by 5.2% year - on - year, slightly lower than the previous quarter [1] - In August 2025, the manufacturing PMI was 49.4%, up 0.1 percentage points from the previous month; the non - manufacturing business activity PMI was 50.3%, up 0.2 percentage points [1][2][20] - In July 2025, M1 and M2 increased by 5.6% and 8.8% year - on - year respectively, showing an upward trend [1] 3.2 Commodity Investment Reference 3.2.1 Comprehensive - Personal consumer loan interest subsidies will be available from September 1st, with multiple banks promoting related products [2] - Many domestic commodity futures showed inventory changes on August 29th, with some increasing and some decreasing [4][5] - China and the US held economic and trade talks, emphasizing cooperation and the management of differences [6] 3.2.2 Metals - As of mid - August 2025, the price of electrolytic copper increased by 0.94% month - on - month [7] - London's basic metals generally rose on August 29th, with domestic copper demand expected to improve [7] - International precious metal futures generally closed higher due to weak US economic data [8] 3.2.3 Coal, Coke, Steel and Minerals - In H1 2025, the coking industry faced difficulties, with most listed coke companies reporting losses [9] - As of mid - August 2025, the prices of most coal products increased, while the price of rebar decreased slightly [9] 3.2.4 Energy and Chemicals - China is promoting policies to support private enterprises in major projects and consumer replacement [11][12] - China has achieved large - scale thermal recovery of offshore heavy oil, with production hitting a record high [12] - As of mid - August 2025, the prices of most oil and gas products decreased [12] 3.2.5 Agricultural Products - As of mid - August 2025, the prices of most agricultural products increased [14][15] - China is strengthening the management of crop varieties and protecting permanent basic farmland [15] - A batch of Russian rapeseed oil was imported into Chengdu, marking a new breakthrough in international grain and oil trade [16] 3.3 Financial News Compilation 3.3.1 Open Market - This week, 22.731 trillion yuan of reverse repurchases will mature, and 1 trillion yuan of 91 - day repurchase agreements will mature on Friday [18] - On August 29th, the central bank conducted 782.9 billion yuan of 7 - day reverse repurchases, resulting in a net investment of 421.7 billion yuan [19] 3.3.2 Important News - The economic sentiment in China continues to expand, and policies are being promoted to support private enterprises and consumer replacement [20] - The sales of TOP100 real estate enterprises from January to August decreased by 13.3% year - on - year, and the market may recover moderately in September [22] - Many small and medium - sized banks have recently cut deposit rates [23] 3.3.3 Bond Market Summary - The bond market was generally strong, with yields of major interest - rate bonds in the inter - bank market declining slightly [26] - Most Vanke bonds rose, and the CSI Convertible Bond Index fell [26] 3.3.4 Foreign Exchange Market - The on - shore RMB rose against the US dollar, while the US dollar index fell slightly [29][30] 3.3.5 Research Report Highlights - After Powell's speech, the market's expectation of a Fed rate cut in September increased [31] - The Trump administration may interfere with the Fed's personnel, potentially leading to monetary easing [31] 3.3.6 Today's Reminder - On September 1st, 121 bonds will be listed, 64 bonds will be issued, 82 bonds will be paid, and 604 bonds will have principal and interest repaid [33][34] 3.4 Stock Market News - Next week, 29 A - shares will be lifted from lock - up, with a total market value of 18.877 billion yuan [35] - In H1 2025, Shanghai - listed companies' revenues decreased slightly, while profits increased [35] - As of the end of August, the scale of Shanghai ETFs exceeded 3.7 trillion yuan, with significant capital inflows [36]

Report Industry Investment Rating - The report does not explicitly mention the overall industry investment rating. However, some institutions have provided ratings for specific sectors: Goldman Sachs maintains an "overweight" stance on Chinese stocks, and Standard Chartered Bank maintains an "overweight" rating on Chinese stocks in its "2025 H2 Global Market Outlook" [36]. Core Viewpoints - The domestic futures market had a mixed performance overnight, with most contracts falling. International precious metals generally rose, while international oil prices slightly declined. The global economic and policy environment is complex, with various factors influencing different markets such as macro - policies, corporate operations, and international trade relations [3][4][5]. Summary by Directory Overnight Night - Market Trends - **Domestic Futures**: Most domestic futures main contracts fell. Soda ash dropped over 2%, and glass, coke, cotton, etc., dropped over 1%. Shanghai silver and caustic soda rose over 1% [3]. - **International Precious Metals**: COMEX gold futures rose 1.13% to $3516.1 per ounce, and COMEX silver futures rose 2.62% to $40.723 per ounce [4]. - **International Oil Prices**: WTI crude oil main contract fell 0.48% to $64.01 per barrel, and Brent crude oil main contract fell 0.28% to $67.48 per barrel [5]. - **London Base Metals**: All London base metals rose. LME zinc rose 1.19%, LME nickel rose 0.93%, etc. [5]. - **International Agricultural Products**: International agricultural product futures had mixed performances. US soybeans rose 0.45%, US corn rose 2.25%, etc. [7]. Important Information Macro Information - As of July 2025, there were 150 futures companies in China, with a trading volume of 10.99 billion lots and an operating income of 4.282 billion yuan in July [9]. - As of August 29, the Shanghai Export Containerized Freight Index dropped 29.7 points, and the China Export Containerized Freight Index dropped 1.6% [9]. - The NDRC will introduce policies to promote private investment and set minimum private investment participation ratios for major projects [9]. - From August 27 - 29, Chinese and US officials held talks on Sino - US economic and trade relations [9]. - In August, China's manufacturing PMI was 49.4%, up 0.1 percentage points from the previous month, and the non - manufacturing business activity index was 50.3%, up 0.2 percentage points [10][12]. - The Fed entered a "quiet period" before its September meeting [12]. Energy and Chemical Futures - From September 1, 2025, the maximum daily opening position for non - futures company members or clients in the caustic soda 2601 contract is 10,000 lots [14]. - Last week, PVC production enterprises' capacity utilization rate was 76.02%, down 1.59% month - on - month [14]. - In June, US crude oil production reached a record high, and LNG production increased by 12,000 barrels per day [14]. Metal Futures - Tin Industry Co., Ltd. will conduct a routine shutdown for equipment maintenance, expected to last no more than 45 days, with little impact on the annual production plan [16][17]. - Last week, copper inventory decreased by 1,950 tons, and aluminum inventory increased by 991 tons [18]. - The US Federal Circuit Court of Appeals ruled that most of Trump's global tariff measures were illegal [18]. Black - Series Futures - The blast furnace operating rate of 247 steel mills was 83.2%, down 0.16 percentage points from last week [20]. - The total inventory of imported iron ore in 45 ports was 137.6302 million tons, down 821,800 tons [20]. - Shanxi Coking Coal's subsidiary had a safety accident and stopped production, with an annual approved capacity of 4 million tons [21]. - This week, the total urban inventory was 8.8916 million tons, up 349,900 tons from last week [23]. - In August, the steel industry PMI was 49.8%, down 0.7 percentage points from the previous month [23]. - Colombia banned coal exports to Israel [23]. Agricultural Product Futures - As of August 29, the self - breeding and self - raising pig farming profit was 32.24 yuan per head, and the profit from purchasing piglets was a loss of 148.41 yuan per head [25]. - Zhengzhou Commodity Exchange revised the rules for fresh apple futures [25]. - India allocated 2.35 million tons of sugar for domestic sales in September 2025, the same as in 2024 [25]. - Indonesia set the reference price for CPO in September at $954.71 per ton, up from August [27]. - In the first half of August, Brazil's central - southern region had a 8.17% year - on - year increase in sugarcane crushing volume [27]. - The ISO expects the global sugar supply shortage in 2025/2026 to narrow significantly to 231,000 tons [28]. - Malaysia's palm oil exports from August 1 - 31 were 1.421486 million tons, up 10.2% from the previous month [29]. Financial Market Finance - Next week, 29 A - share stocks will face unlocking, with a total unlocking market value of 18.877 billion yuan, down 73.51% week - on - week [31]. - In H1 2025, Shanghai - listed companies' operating income was 24.68 trillion yuan, down 1.3% year - on - year, and net profit was 2.39 trillion yuan, up 1.1% [33]. - As of the end of August, the scale of Shanghai ETFs exceeded 3.7 trillion yuan, with a net inflow of over 350 billion yuan this year [33]. - As of June 30, 2025, the five A - share listed insurance companies' stock investment scale was nearly 1.8 trillion yuan, up 405.356 billion yuan from the end of 2024 [35]. - In August, A - shares continued to rise. Institutions expect the market to be volatile in September and focus on resource sectors, innovation drugs, etc. [36]. - Many foreign financial institutions are optimistic about the Chinese market. Hedge funds are net buyers of Chinese stocks [36]. - In the first eight months, the A - share market was strong, and the average return of active equity funds was 23.83% [36]. - Hesai Technology passed the Hong Kong Stock Exchange's hearing and plans to list in Hong Kong [37]. - Hefei Xinqi Microelectronics Equipment Co., Ltd. and Easy Health Group submitted IPO applications to the Hong Kong Stock Exchange [37]. Industry - Since August, nearly 20 small and medium - sized banks have lowered deposit interest rates [38]. - From January to August, the sales of TOP100 real estate enterprises were 2.32705 trillion yuan, down 13.3% year - on - year [40]. - In August, the inventory warning index for Chinese auto dealers was 57.0%, up 0.8 percentage points year - on - year [40]. - In 2025, China's total box office (including overseas) exceeded 40 billion yuan [40]. - The mother - fund market cooled significantly this year, with 33 new mother - funds established [41]. - Shanghai's leading commercial health insurance companies are developing new group insurance products [41]. Overseas - Trump's global tariff policy and the lawsuit to remove Fed Governor Cook are facing the US Supreme Court's final ruling [42]. - Japan and the US are discussing a package deal including tariff reduction and a $550 billion investment plan [44]. - ECB Governing Council member Rehn said inflation risks are "downward - biased" [44]. International Stock Market - Tata Capital will launch a $2 billion IPO in September [45]. Commodity - Malaysia's palm oil exports in August were 1.421486 million tons, up 10.22% month - on - month [46]. Bond - Yuzhou Group's overseas debt restructuring became effective, involving about $6.68 billion in debt, and is expected to reduce the repayment pressure by about $3.5 billion [47]. Foreign Exchange - In the past two weeks, the RMB has strengthened against the US dollar, driven by the weakening US dollar index and narrowing Sino - US interest rate differentials [49]. - The Canadian dollar has risen 4.68% against the US dollar this year, being the worst - performing G10 currency [50].